Login to Your Account

So Far So Good

Vaximm Gets Positive Readout on Oral Cancer Vaccine VXM01

By Cormac Sheridan
Staff Writer

Monday, February 11, 2013
Top-line data from a Phase I/II trial of Vaximm AG's oral cancer vaccine VXM01 in patients with advanced pancreatic cancer provide the first clinical indications that the vaccine can elicit an immune response.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription